Genetic testing for chemotherapy in non-small cell lung cancer

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 97-102

  Rosell, Rafael ^a   Taron, Miquel ^a   Alberola, Vicente ^b   Massuti, Bartomeu ^c   Felip, Enriqueta ^d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cisplatin; ERCC 1; Gemcitabine; NER; NSCLC; XPD

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; GEMCITABINE; GLUTATHIONE; METALLOTHIONEIN; NUCLEOTIDE; OXALIPLATIN;

CANCER CHEMOTHERAPY; CANCER GENETICS; CARCINOGENESIS; COLORECTAL CARCINOMA; CONFERENCE PAPER; DETOXIFICATION; DNA ADDUCT; DNA REPAIR; DRUG MECHANISM; DRUG SCREENING; EXCISION REPAIR; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CARCINOMA;

EID: 0038350391     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00151-X     Document Type: Conference Paper

References (23)

1. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98.
2. Rosell R., Gatzemeier U., Betticher D.C., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. 13:2002;1539-1549.
3. Phillips D.H. The formation of DNA adducts. Alison M.R. The cancer handbook. 2002;293-307 Nature Publishing Group, London.
4. Siddik Z.H. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. Alison M.R. The cancer handbook. 2002;1295-1313 Nature Publishing Group, London.
5. Hanawalt P.C. Controlling the efficiency of excision repair. Mut. Res. 485:2001;3-13.
6. May A., Nairn R.S., Okumoto D.S., et al. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem. 268:1993;1650-1657.
7. McKay B.C., Ljungman M., Rainbow A.J. Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene. 17:1998;545-555.
8. Cullinane C., Mazur S.J., Essigmann J.M., et al. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry. 38:1999;6204-6212.
9. Conforti G., Nardo T., D'Incalci M., Stefanini M. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene. 19:2000;2714-2720.
10. Takebayashi Y., Nakayama K., Kanzaki A., et al. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett. 174:2001;115-125.
11. McKay B.C., Becerril C., Ljungman M. p53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene. 20:2001;6805-6808.
12. Furuta T., Ueda T., Aune G., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62:2002;4899-4902.
13. Takebayashi Y., Pourquier P., Zimonjic D.B., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7:2001;961-966.
14. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer. 92:2001;583-588.
15. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16:1998;309-316.
16. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 119:2001;4298-4304.
17. Lord R.V.N., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin. Cancer Res. 8:2002;2286-2291.
18. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61:2001;1354-1357.
19. Bosken C.H., Wei Q., Amos C.I., Spitz M.R. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 94:2002;1091-1099.
20. Poirier M.C., Reed E., Litterst C.L., et al. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 52:1992;149-153.
21. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl. J. Med. 326:1992;524-530.
22. Van de Vaart P.J.M., Belderbos J., de Jong D., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int. J. Cancer (Pred. Oncol.). 89:2000;160-166.
23. Rajewsky M.F., Müller R. DNA repair and the cell cycle as targets in cancer therapy. Alison M.R. The cancer handbook. 2002;1507-1519 Nature Publishing Group, London.